U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H35NO4.ClH
Molecular Weight 450.011
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Norbuprenorphine hydrochloride

SMILES

Cl.CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]4CC5=CC=C(O)C6=C5[C@@]3(CCN4)[C@H]2O6

InChI

InChIKey=HAFFMAAVKOFVLD-GAZCGFTGSA-N
InChI=1S/C25H35NO4.ClH/c1-21(2,3)22(4,28)16-13-23-8-9-25(16,29-5)20-24(23)10-11-26-17(23)12-14-6-7-15(27)19(30-20)18(14)24;/h6-7,16-17,20,26-28H,8-13H2,1-5H3;1H/t16-,17-,20-,22+,23-,24+,25-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C25H35NO4
Molecular Weight 413.5497
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Norbuprenorphine is a major metabolite of buprenorphine and potent agonist of μ, δ, and κ opioid receptors. Norbuprenorphine is the only known active metabolite of buprenorphine. It has been shown to be a respiratory depressant in rats, but only at concentrations at least 50-fold greater than those observed following application to humans of BuTrans 20 mcg/h. Compared with buprenorphine, norbuprenorphine causes minimal antinociception but greater respiratory depression. In rats, nor-buprenorphine had 1/50th the analgesic potency of buprenor-phine but 10-fold greater respiratory depressant potency. Norbuprenorphine is an in vitro substrate of the efflux transporter P-glycoprotein (Mdr1). Norbuprenorphine is an in vitro and in vivo substrate of P-glycoprotein. P-glycoprotein-mediated efflux influences brain access and antinociceptive, but not the respiratory, effects of norbuprenorphine.

CNS Activity

Curator's Comment: Norbuprenorphine contributes to the central effects seen after chronic BUP administration as this study demonstrated its entry into the sheep brain.

Approval Year

PubMed

PubMed

TitleDatePubMed
Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.
2005
Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro.
2003-06
Patents

Sample Use Guides

Sheep were administered 0.6 mg kg(-1) Norbuprenorphine as 4-min i.v. infusions.
Route of Administration: Intravenous
Compared with buprenorphine, norbuprenorphine demonstrated a lower inhibitory potency with CYP2D6(22.4% inhibition at 20uM norbuprenorphine) and CYP3A4 (13.6%inhibition at 20uM) in microsomes from human cDNA-expressing lymphoblast cells.
Substance Class Chemical
Created
by admin
on Wed Apr 02 11:22:13 GMT 2025
Edited
by admin
on Wed Apr 02 11:22:13 GMT 2025
Record UNII
ZJ6Q3WB4RJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
6,14-Ethenomorphinan-7-methanol, ?-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-?-methyl-, hydrochloride, (?S,5?,7?)-
Preferred Name English
Norbuprenorphine hydrochloride
Common Name English
Code System Code Type Description
FDA UNII
ZJ6Q3WB4RJ
Created by admin on Wed Apr 02 11:22:13 GMT 2025 , Edited by admin on Wed Apr 02 11:22:13 GMT 2025
PRIMARY
PUBCHEM
166177205
Created by admin on Wed Apr 02 11:22:13 GMT 2025 , Edited by admin on Wed Apr 02 11:22:13 GMT 2025
PRIMARY
CAS
209963-02-0
Created by admin on Wed Apr 02 11:22:13 GMT 2025 , Edited by admin on Wed Apr 02 11:22:13 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE